FCCC LOGO Faculty Publications
Ozols Robert F
Systemic therapy for avarian cancer: current status and new treatments
Seminars in Oncology. 2006 ;33(2, Suppl. 6) :S3-S11
PMID: AN 2006:660193   
Back to previous list
Abstract
Current systemic therapy for ovarian cancer consists of a combination of carboplatin and paclitaxel. While the majority of patients achieve clin. complete remission after six cycles of chemotherapy, the relapse rate stands at over 50%. Median survival time for patients after recurrence is approx. 2 years. New treatment approaches for patients with advanced ovarian cancer include consolidation and maintenance therapy, i.p. administration of cytotoxic agents, new combination chemotherapy regimens, the development of new cytotoxic agents, and mol.-targeted therapies. These agents will be evaluated either singularly or with chemotherapy. Currently, the Gynecol. Oncol. Group is evaluating a combination of bevacizumab together with paclitaxel and carboplatin in previously untreated patients with advanced ovarian cancer. This trial is based on phase II data that suggest that bevacizumab as a single agent has significant activity in patients with recurrent ovarian cancer. In addn., the Gynecol. Oncol. Group will be conducting phase II trials of different combinations of i.p. chemotherapy in an effort to decrease toxicity assocd. with current i.p. regimens that have shown an improvement in survival in patients with small-vol. stage III disease. The Gynecol. Oncol. Group will also be conducting a trial of maintenance therapy in patients who enter clin. complete remission with paclitaxel plus carboplatin, comparing observation with monthly paclitaxel or monthly paclitaxel poliglumex. Novel new cytotoxic and biol. agents are also being evaluated as single agents in phase II trials in patients with recurrent ovarian cancer. [on SciFinder (R)]
Notes
1 Pharmacology Fox Chase Cancer Center,Philadelphia,PA,USA. Journal; General Review 0093-7754 written in English.